|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang S, Du H and Li G: Significant
prognostic value of circulating tumor cells in esophageal cancer
patients: A meta-analysis. Oncotarget. Feb 2–2017.(Epub ahead of
print).
|
|
3
|
Gakis G, Todenhöfer T and Stenzl A: The
prognostic value of hematological and systemic inflammatory
disorders in invasive bladder cancer. Curr Opin Urol. 21:428–433.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stone RL, Nick AM, McNeish IA, Balkwill F,
Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot
CV, Coward J, et al: Paraneoplastic thrombocytosis in ovarian
cancer. N Engl J Med. 366:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaloglu S, Guraslan H, Tekirdag AI,
Dagdeviren H and Kaya C: Relation of preoperative thrombocytosis
between tumor stage and grade in patients with endometrial cancer.
Eurasian J Med. 46:164–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borsig L: The role of platelet activation
in tumor metastasis. Expert Rev Anticancer Ther. 8:1247–1255. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li FX, Wei LJ, Zhang H, Li SX and Liu JT:
Significance of thrombocytosis in clinicopathologic characteristics
and prognosis of gastric cancer. Asian Pac J Cancer Prev.
15:6511–6517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu M, Liu L, Zhang BL, Chen Q, Ma XL, Wu
YK, Liang CS, Niu ZM, Qin X and Niu T: Pretreatment thrombocytosis
as a prognostic factor in women with gynecologic malignancies: a
meta-analysis. Asian Pac J Cancer Prev. 13:6077–6081. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sobin LH and Fleming ID: TNM
classification of Malignant tumors, fifth edition (1997). Union
internationale contre le cancer and the american joint committee on
cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
11
|
Zoodsma M, Nolte IM, Te Meerman GJ, De
Vries EG and Van der Zee AG: HLA genes and other candidate genes
involved in susceptibility for (pre)neoplastic cervical disease.
Int J Oncol,. 26:769–784. 2005.
|
|
12
|
Hu C, Chen R, Chen W, Pang W, Xue X, Zhu G
and Shen X: Thrombocytosis is a significant indictor of
hypercoagulability, prognosis and recurrence in gastric cancer. Exp
Ther Med. 8:125–132. 2014.PubMed/NCBI
|
|
13
|
Hwang SG, Kim KM, Cheong JH, Kim HI, An
JY, Hyung WJ and Noh SH: Impact of pretreatment thrombocytosis on
blood-borne metastasis and prognosis of gastric cancer. Eur J Surg
Oncol. 38:562–567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Huang X, Chen Y, Jin X, Li Q and
Yi TN: Prognostic value of TP/PD-ECGF and thrombocytosis in gastric
carcinoma. Eur J Surg Oncol. 38:568–573. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim M, Chang H, Yang HC, Kim YJ, Lee CT,
Lee JH, Jheon S, Kim K, Chung JH and Lee JS: Preoperative
thrombocytosis is a significant unfavorable prognostic factor for
patients with resectable non-small cell lung cancer. World J Surg
Oncol. 12:372014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maráz A, Furák J, Varga Z, Kahán Z,
Tiszlavicz L and Hideghéty K: Thrombocytosis has a negative
prognostic value in lung cancer. Anticancer Res. 33:1725–1729.
2013.PubMed/NCBI
|
|
17
|
Tomita M, Shimizu T, Hara M, Ayabe T and
Onitsuka T: Prognostic impact of thrombocytosis in resectable
non-small cell lung cancer. Interact Cardiovasc Thorac Surg.
7:613–615. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pedersen LM and Milman N: Prognostic
significance of thrombocytosis in patients with primary lung
cancer. Eur Respir J. 9:1826–1830. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Venkatramani V, Panda A and Kekre NS: Is
thrombocytosis a useful prognostic marker in renal cell carcinoma?
Results of a single-center retrospective analysis. Indian J Urol.
31:42–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brookman-May S, May M, Ficarra V, Kainz
MC, Kampel-Kettner K, Kohlschreiber S, Wenzl V, Schneider M, Burger
M, Wieland WF, et al: Does preoperative platelet count and
thrombocytosis play a prognostic role in patients undergoing
nephrectomy for renal cell carcinoma? Results of a comprehensive
retrospective series. World J Urol. 31:1309–1316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wosnitzer M, Polland A, Hai Q, Hruby G and
McKiernan J: Role of preoperative platelet level in clinical and
pathological outcomes after surgery for renal cortical
malignancies. BJU Int. 108:73–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suppiah R, Shaheen PE, Elson P, Misbah SA,
Wood L, Motzer RJ, Negrier S, Andresen SW and Bukowski RM:
Thrombocytosis as a prognostic factor for survival in patients with
metastatic renal cell carcinoma. Cancer. 107:1793–1800. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Göğüş C, Baltaci S, Filiz E, Elhan A and
Bedük Y: Significance of thrombocytosis for determining prognosis
in patients with localized renal cell carcinoma. Urology.
63:447–450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inoue K, Kohashikawa K, Suzuki S, Shimada
M and Yoshida H: Prognostic significance of thrombocytosis in renal
cell carcinoma patients. Int J Urol. 11:364–367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Symbas NP, Townsend MF, El-Galley R, Keane
TE, Graham SD and Petros JA: Poor prognosis associated with
thrombocytosis in patients with renal cell carcinoma. BJU Int.
86:203–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim HJ, Choi GS, Park JS, Park S, Kawai K
and Watanabe T: Clinical significance of thrombocytosis before
preoperative chemoradiotherapy in rectal cancer: Predicting
pathologic tumor response and oncologic outcome. Ann Surg Oncol.
22:513–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo T, Krzystanek M, Szallasi Z and
Szallasi A: Thrombocytosis portends adverse prognostic significance
in patients with stage II colorectal carcinoma. F1000Res.
3:1802014.PubMed/NCBI
|
|
28
|
Lin MS, Huang JX, Zhu J and Shen HZ:
Elevation of platelet count in patients with colorectal cancer
predicts tendency to metastases and poor prognosis.
Hepatogastroenterology. 59:1687–1690. 2012.PubMed/NCBI
|
|
29
|
Cravioto-Villanueva A, Luna-Perez P,
Gutierrez-de la Barrera M, Martinez-Gómez H, Maffuz A, Rojas-Garcia
P, Perez-Alvarez C, Rodriguez-Ramirez S, Rodriguez-Antezana E and
Ramirez-Ramirez L: Thrombocytosis as a predictor of distant
recurrence in patients with rectal cancer. Arch Med Res.
43:305–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sasaki K, Kawai K, Tsuno NH, Sunami E and
Kitayama J: Impact of preoperative thrombocytosis on the survival
of patients with primary colorectal cancer. World J Surg.
36:192–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh PB, Ragavan N, Ashton KM, Basu P,
Nadeem SM, Nicholson CM, Krishna RK, Matanhelia SS and Martin FL:
Quantified gene expression levels for phase I/II metabolizing
enzyme and estrogen receptor levels in benign prostate from cohorts
designated as high-risk (UK) versus low-risk (India) for
adenocarcinoma at this organ site: A preliminary study. Asian J
Androl. 12:203–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Choe KS, Correa D, Jani AB and Liauw SL:
The use of anticoagulants improves biochemical control of localized
prostate cancer treated with radiotherapy. Cancer. 116:1820–1826.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Men H, Liang C and Yu M: Thrombocytosis as
a prognostic factor in patients with renal cell carcinoma: A
meta-analysis of literature. J Cancer Res Ther. 11:67–72. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Verheul HM, Jorna AS, Hoekman K,
Broxterman HJ, Gebbink MF and Pinedo HM: Vascular endothelial
growth factor-stimulated endothelial cells promote adhesion and
activation of platelets. Blood. 96:4216–4221. 2000.PubMed/NCBI
|
|
35
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kuenen BC, Levi M, Meijers JC, Kakkar AK,
van Hinsbergh VW, Kostense PJ, Pinedo HM and Hoekman K: Analysis of
coagulation cascade and endothelial cell activation during
inhibition of vascular endothelial growth factor/vascular
endothelial growth factor receptor pathway in cancer patients.
Arterioscler Thromb Vasc Biol. 22:1500–1505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roselli M, Mineo TC, Basili S, Mariotti S,
Martini F, Bellotti A, Ambrogi V, Spila A, D'Alessandro R,
Gazzaniga PP, et al: Vascular endothelial growth factor (VEGF-A)
plasma levels in non-small cell lung cancer: Relationship with
coagulation and platelet activation markers. Thromb Haemost.
89:177–184. 2003.PubMed/NCBI
|
|
38
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nat Rev Cancer.
11:123–134. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mehta P: Potential role of platelets in
the pathogenesis of tumor metastasis. Blood. 63:55–63.
1984.PubMed/NCBI
|
